Back to News
Canaccord cuts Ultragenyx stock price target on trial failure
Source: Investing.com
No news content was available (article text returned as '403'), so no themes, financial impacts, or sentiment can be reliably extracted.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- ‘I have a big decision to make’: Trump had a ‘good meeting’ with Iranian officials warning he may ‘annihilate the Islamic Republic’
- Bank of America says Brent crude oil could top $150 a barrel if Iran war disruptions persist
- The bond market is flashing a warning for stocks. These sectors are already wobbling.
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- Qatar’s emir urges diplomacy as Gulf at ‘one of the most dangerous phases’